- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00377546
Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%
September 23, 2008 updated by: Innovative Medical
To compare the penetration of three different NSAIDs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females scheduled to undergo Vitrectomy surgery
- Likely to complete all study visits and able to provide informed consent
- Visual potential of 20/25 or better
Exclusion Criteria:
- Known contraindications to any study medication or ingredients
- Active ocular diseases or uncontrolled systemic disease
- Active ocular allergies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrey Heier, MD, Ophthalmic Consultants of Boston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 14, 2006
First Submitted That Met QC Criteria
September 14, 2006
First Posted (Estimate)
September 18, 2006
Study Record Updates
Last Update Posted (Estimate)
September 25, 2008
Last Update Submitted That Met QC Criteria
September 23, 2008
Last Verified
September 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketorolac
- Bromfenac
- Nepafenac
Other Study ID Numbers
- 5264
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitrectomy
-
VISTA OphthalmicsCBCC Global ResearchActive, not recruitingVitrectomyUnited States
-
ThromboGenicsCompletedVitrectomyUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Vanderbilt University Medical CenterAlcon ResearchCompleted
-
ThromboGenicsCompleted
-
Alcon ResearchCompleted
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
AllerganCompletedVitrectomyUnited States, Czech Republic
-
Kocaeli UniversityCompleted
-
Eyegate Pharmaceuticals, Inc.Completed
Clinical Trials on Nepafenac
-
Jaeb Center for Health ResearchNational Eye Institute (NEI)CompletedDiabetic Macular EdemaUnited States
-
Actavis Inc.Completed
-
Alcon ResearchTerminated
-
Alcon ResearchCompleted
-
Melissa ToyosBausch & Lomb IncorporatedCompletedInflammation | Cataract | Retinal EdemaUnited States
-
Alcon ResearchCompletedEpiretinal MembraneUnited States
-
Intuor Technologies, Inc.CompletedCystoid Macular Edema
-
Universiti Sains MalaysiaCompleted